Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Seventeen patients with advanced progressive prostatic cancer who had relapsed or failed to respond to conventional endocrine therapy with oestrogens, orchiectomy or antiandrogens were treated with the LHRH analogue, ICI 118630. No significant objective tumour responses were seen, though 11 of 15 patients who presented with symptomatic metastatic bone pain had rapid short-term pain relief. The lack of objective clinical response seen in this study indicates no justification for the use of LHRH analogues in this group of patients. Though a significant subjective response was seen there was no added advantage over regular analgesics.
D000135:Acid Phosphatase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000698:Analgesia; D001859:Bone Neoplasms / Q000556:secondary; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017273:Goserelin; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D006728:Hormones; D017273:Goserelin; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D002064:Buserelin